Press Releases
Press Releases
-
June 12, 2021
Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis -
June 10, 2021
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C -
June 4, 2021
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation -
June 4, 2021
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study -
May 19, 2021
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021 -
May 14, 2021
Gilead Sciences to Present at Upcoming Investor Conferences -
May 6, 2021
Gilead Sciences to Present at Upcoming Investor Conferences -
April 29, 2021
Gilead Sciences Announces Second Quarter 2021 Dividend -
April 29, 2021
Gilead Sciences Announces First Quarter 2021 Financial Results -
April 26, 2021
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India